<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PRF</journal-id>
<journal-id journal-id-type="hwp">spprf</journal-id>
<journal-id journal-id-type="nlm-ta">Perfusion</journal-id>
<journal-title>Perfusion</journal-title>
<issn pub-type="ppub">0267-6591</issn>
<issn pub-type="epub">1477-111X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0267659112437775</article-id>
<article-id pub-id-type="publisher-id">10.1177_0267659112437775</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prolonged warm ischemia for transfusion-free arterial switch and ventricular septal defect surgery in a 4.5-Kg baby</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rubatti</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0267659112437775">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Durandy</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff2-0267659112437775">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0267659112437775"><label>1</label>Anesthesiology Department, Institut Hopitalier Jacques Cartier, Massy, France</aff>
<aff id="aff2-0267659112437775"><label>2</label>Perfusion and Intensive Care Department, Institut Hopitalier Jacques Cartier, Massy, France</aff>
<author-notes>
<corresp id="corresp1-0267659112437775">Y Durandy Institut Hospitalier Jacques Cartier Avenue du Noyer Lambert 91300, Massy France Email: <email>iciprea@icip.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>3</issue>
<fpage>230</fpage>
<lpage>234</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Blood-free pediatric surgery is increasingly used for surgical correction of simple cardiopathies. Herein, we describe a complex cardiopathy, arterial switch operation and ventricular septal defect, with pre-operative thrombocytopenia in a 4.5 Kg baby treated with warm surgery and intermittent warm blood microplegia without any blood product. Bypass time was 89 min and aortic cross-clamp time 61 min. The maximal length of warm ischemia (time between microplegia injections) was 42 minutes. The postoperative course was uneventful. The patient was weaned off the ventilator after 7 hours, was discharged from the ICU on day 2 and was discharged from the hospital on day 7. The two main factors involved in this result were high pre-operative hemoglobin level and bypass technique with small prime volume, microplegia and warm perfusion. However, the success of this challenging case is also the result of teamwork and of rigorous patient care.</p>
</abstract>
<kwd-group>
<kwd>warm pediatric surgery</kwd>
<kwd>warm ischemia</kwd>
<kwd>intermittent warm blood microplegia</kwd>
<kwd>blood- free pediatric surgery</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0267659112437775" sec-type="intro">
<title>Introduction</title>
<p>Blood transfusions are associated with potentially life-threatening complications<sup><xref ref-type="bibr" rid="bibr1-0267659112437775">1</xref>,<xref ref-type="bibr" rid="bibr2-0267659112437775">2</xref></sup>. Like many other surgical centers, we have developed blood conservation strategies to avoid or decrease the need for transfusions. We use a commercially available, dedicated, pediatric, two-level heart-lung machine that helps to minimize the bypass circuit (<xref ref-type="fig" rid="fig1-0267659112437775">Figure 1</xref>). The upper level carries the suction roller pumps and the lower level a double-head arterial and blood-microplegia roller pump. Continuous vacuum-assisted venous drainage is used, allowing a high position of the membrane oxygenator. The top of the cardiotomy reservoir is at the patient’s atrial level<sup><xref ref-type="bibr" rid="bibr3-0267659112437775">3</xref></sup>. The prime volume of the circuit, including the cardioplegia line, is 125 mL for babies up to 7 Kg. The bypass circuit includes a Kids D100 membrane oxygenator (Sorin Group, Mirandola, Italy) with a prime volume of 31 mL, arterial and venous lines composed of 3/16-inch diameter silicon non-heparin-coated tubing with a total prime volume of 36 mL, and a cardioplegia circuit with a prime volume of 5 mL (<xref ref-type="fig" rid="fig2-0267659112437775">Figure 2</xref>). The volume of the ¼-inch diameter raceway tubing is 15 mL. The volume in the cardiotomy reservoir before bypass is about 40 mL. Blood-free prime is used whenever the estimated nadir hemoglobin level is likely to exceed 8 g/dL during bypass. In our unit, since 2001, warm surgery has been consistently used for all types of cardiopathies. The prime solution is heated to 37°C and the water heater settled to 37.5°C during the whole bypass time. During bypass, temperature being stable, blood flow is maintained constant at 2.7 l/min/m<sup>2</sup>. Intermittent warm blood microplegia involves oxygenated warm blood being diverted from the origin of the arterial line via an occlusive roller pump and the arresting agent injected downstream of the roller pump via an electrical syringe (<xref ref-type="fig" rid="fig2-0267659112437775">Figure 2</xref>). The cardioplegia circuit is composed of small tubing equivalent to infusion line tubing and a raceway for the roller pump of 1/8 inch in diameter.</p>
<fig id="fig1-0267659112437775" position="float">
<label>Figure 1.</label>
<caption>
<p>Double-level heart-lung machine, Stöckert S5 (Sorin Group, Munich, Germany)</p>
<p>Lower level:</p>
<p>- 1 Double rotor pump, arterial and cardioplegia pump; for older children the single rotor pump is used as the arterial pump.</p>
<p>- 2 Membrane oxygenator</p>
<p>Upper level:</p>
<p>- 3 Left vent pump and suckers - three pumps (one single rotor and two small rotors)</p>
<p>- 4 Patient’s thorax</p>
<p>- 5 Vacuum regulator</p>
<p>Right part</p>
<p>- A heightening device manufactured by Stöckert</p>
</caption>
<graphic xlink:href="10.1177_0267659112437775-fig1.tif"/>
</fig>
<fig id="fig2-0267659112437775" position="float">
<label>Figure 2.</label>
<caption>
<p>Diagram of the bypass circuit</p>
</caption>
<graphic xlink:href="10.1177_0267659112437775-fig2.tif"/>
</fig>
<p>The arresting agent is commercially available (Pharmacie Centrale des Hôpitaux de Paris AP-HP, Paris, France) and composed of potassium 0.8 mmol per ml, magnesium 0.8 mmol per ml, chloride 2.45 mmol per ml and procaine 0.05 mmol per ml. The interval time between injections was gradually increased from 15 minutes during our initial experience of warm surgery to 35 to 40 minutes currently. Cardioplegia flow is between 5 and 10% of the total bypass flow. A simple nomogram has been developed with the roller pump (driving blood) speed in ml per min equivalent to the electrical syringe (driving arresting agent) speed in ml per hour<sup><xref ref-type="bibr" rid="bibr4-0267659112437775">4</xref></sup>. The result is a ratio of blood to arresting agent of 60/1. The blood withdrawn from the circuit is returned to the cardiotomy reservoir, therefore, the hydric balance of the microplegia is limited to the few milliliters of arresting agent injected.</p>
</sec>
<sec id="section2-0267659112437775" sec-type="cases">
<title>Case report</title>
<p>A 10-month-old Algerian boy weighing 4.5 kg was referred to our unit for surgical repair of transposition of the great arteries with ventricular septal defect. In addition to severe malnutrition, this patient had cyanosis with pulse oximetry values around 65%, polycythemia with a hemoglobin level of 18 g/dL, and thrombocytopenia with a platelet count of 20,000/mL. A hemoglobin level of about 13 g/dL was expected after dilution with a blood-free prime and cardiopulmonary bypass was, therefore, initiated with a prime composed of 50% Ringer lactate solution and 50% hydroxyethyl starch with an added 2000 IU of heparin. To increase the pH of the prime to a physiological level, 3 mEq of sodium bicarbonate was added. Anesthesia was performed with inhaled sevoflurane followed by a continuous infusion of sufentanyl and intermittent injections of flunitrazepam and pancuronium bromide. The prime was heated to 37°C and the temperature of the water heater was set at 37.5°C throughout the bypass time. A size 11 teflon arterial cannula (Soframedica, Condrieu, France) was inserted in the ascending aorta and the vena cavae were individually cannulated with metallic cannulas, 3 mm and 4 mm external diameter in the superior and inferior vena cava, respectively. Perfusion flow was 0.7 l/min during bypass, equivalent to the targeted flow of 2.7 l/min/m<sup>2</sup>. Vacuum-assisted venous drainage was continuously monitored via a pressure set connected to the heart-lung machine, Stöckert S5 (Sorin Group, Munich, Germany). The maximum negative pressure was -32 mmHg. Warm autologous blood microplegia was infused for 90 seconds following aortic cross-clamping and, 42 minutes later, a further 60-second infusion was given. The hydric balance of the two injections of microplegia was positive at 1.75 ml. The total aortic cross-clamp time was 61 minutes and the total bypass time was 89 minutes. During bypass, the nadir hemoglobin level was 13.8 g/dl. Inotropic support was initiated before weaning off bypass with 10 μg/Kg/min of enoximone. At the end of the bypass, the arterial line was connected to a blood bag to collect, without any alteration, the blood remaining in the circuit. All this blood was transfused during chest closure and, later, in the intensive care unit (ICU).</p>
<p>The postoperative course was uneventful. The patient was weaned off the ventilator after 7 hours and off inotropic support after 36 hours. During the first 12 hours, blood loss was 68 mL, despite a postoperative platelet count of 10,000/ml. The patient was discharged from the ICU on day 2 and from the hospital on day 7. No blood product was used at any time during the hospital stay. <xref ref-type="table" rid="table1-0267659112437775">Table 1</xref> reports the main postoperative laboratory data.</p>
<table-wrap id="table1-0267659112437775" position="float">
<label>Table 1.</label>
<caption>
<p>Postoperative laboratory data</p>
</caption>
<graphic alternate-form-of="table1-0267659112437775" xlink:href="10.1177_0267659112437775-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">ICU admission</th>
<th align="left">7 hours</th>
<th align="left">Day 1</th>
<th align="left">Day 2</th>
<th align="left">Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood lactate mmol/L</td>
<td>3.7</td>
<td>1.9</td>
<td>1.7</td>
<td>1.6</td>
<td/>
</tr>
<tr>
<td>Hemoglobin g/dL</td>
<td>13.5</td>
<td>12.7</td>
<td>12.3</td>
<td>11.1</td>
<td>12</td>
</tr>
<tr>
<td>Platelet count /mL</td>
<td>10 000</td>
<td/>
<td/>
<td/>
<td>376 000</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-0267659112437775">
<title>Comments</title>
<p>Blood-free bypass priming is becoming more and more frequently used in pediatric cardiac surgery. However, patients may need transfusions during or following surgery and blood-free surgery throughout the whole hospital stay is more often observed in simple cardiopathies. Successful blood-free surgery is teamwork, including everyone involved in patient diagnosis, therapy and care. Caution must be constant to avoid bleeding and blood wasting: control of bleeding in the catheterization laboratory, limited blood samples for biological exams, avoidance of excessive vasodilatation with anesthetic drugs, small prime volume, and compliance to recommendation for blood transfusion, surgical hemostasis, and avoidance of continuous sedation during intensive care stay and short time to extubation.</p>
<p>While it is commonly admitted that a reduction in prime volume is efficient in decreasing blood transfusion, there is no consensus about prime composition. In the literature, the prime composition is crystalloid without albumin or colloid<sup><xref ref-type="bibr" rid="bibr5-0267659112437775">5</xref>-<xref ref-type="bibr" rid="bibr7-0267659112437775">7</xref></sup> or a mixture of albumin and crystalloid<sup><xref ref-type="bibr" rid="bibr8-0267659112437775">8</xref></sup>. Prime composed only of Ringer’s solution, when compared to prime with hydroxyethyl starch or albumin, is associated with greater somatic and pulmonary fluid accumulation<sup><xref ref-type="bibr" rid="bibr9-0267659112437775">9</xref></sup>. Furthermore, with lower substituted novel hydroxyethyl starch, (molecular weight 130 to 150 kDaltons and molar substitution of 0.5 to 0.4) most randomized studies have failed to show any clinically significant bleeding<sup><xref ref-type="bibr" rid="bibr10-0267659112437775">10</xref></sup>. Albumin and hydroxyethyl starch are considered equivalent<sup><xref ref-type="bibr" rid="bibr9-0267659112437775">9</xref></sup>, and hydroxyethyl starch is a safe additive to priming solution<sup><xref ref-type="bibr" rid="bibr11-0267659112437775">11</xref></sup>, as well as an interesting alternative to more expensive albumin solution<sup><xref ref-type="bibr" rid="bibr12-0267659112437775">12</xref></sup>.</p>
<p>Small prime volume perfusion must be combined with a limitation in volume infusion. One method to limit volume infusion following cardiopulmonary bypass is to prevent low cardiac output state and to minimize inflammation. To enhance ventricular performance, the first step of low cardiac output state therapy is volume infusion. Volume infusion with crystalloid or colloid decreases hemoglobin level and, therefore, increases the risk of need for blood transfusion. Since the Primacorp study, we know that preventive infusion of phosphodiesterase III inhibitor significantly reduces the incidence of postoperative low cardiac output state<sup><xref ref-type="bibr" rid="bibr13-0267659112437775">13</xref></sup>. In both our experience and the literature, enoximone is the most potent product in this therapeutic class<sup><xref ref-type="bibr" rid="bibr14-0267659112437775">14</xref>,<xref ref-type="bibr" rid="bibr15-0267659112437775">15</xref></sup> and probably the best way to avoid or limit postoperative cardiac insufficiency.</p>
<p>Systemic inflammation is constant, following cardiopulmonary bypass. Blood transfusion, ischemia reperfusion, and polymers used for cardiopulmonary bypass are the three main factors involved in inflammation. Medical grade silicone is one of the most biocompatible polymers. Polyvinyl chloride, the most commonly used polymer for a cardiopulmonary bypass circuit, releases a toxic product (di,2,ethylhexylphthalate [DEHP]) during cardiopulmonary bypass to a level that may exceed the safety limit<sup><xref ref-type="bibr" rid="bibr16-0267659112437775">16</xref></sup>. The benefit of heparin-coated tubing on release of DEHP is still unclear<sup><xref ref-type="bibr" rid="bibr17-0267659112437775">17</xref></sup> and, furthermore, DEHP is pro-inflammatory in blood and increases postoperative bleeding<sup><xref ref-type="bibr" rid="bibr18-0267659112437775">18</xref></sup>. For those reasons we have decided to limit as much as possible blood contact with polyvinyl chloride and to use a silicone bypass circuit.</p>
<p>In our clinical experience, prolonged warm ischemia proves to be safe. Previous works in adults during coronary bypass predicted that clinically safe warm ischemia was limited to 13 minutes<sup><xref ref-type="bibr" rid="bibr19-0267659112437775">19</xref></sup>. However, the quality of myocardial protection with only antegrade cardioplegia in patients with coronary stenosis is questionable and likely to vary between patients. Furthermore, another study demonstrates that ischemic time may be extended to 25 minutes by adding magnesium sulfate to the arresting solution<sup><xref ref-type="bibr" rid="bibr20-0267659112437775">20</xref></sup>. One experimental study showed no significant difference in the change of venous pH, lactate production, creatine kinase and troponin T release between two groups of dogs after 5, 10, 20 and 40 minutes of warm ischemia<sup><xref ref-type="bibr" rid="bibr21-0267659112437775">21</xref></sup>. A better systolic function was found after warm blood cardioplegia compared to cold blood cardioplegia<sup><xref ref-type="bibr" rid="bibr22-0267659112437775">22</xref></sup> and clinical and laboratory findings suggest that warm blood cardioplegia may be superior in protecting ventricular function during aerobic arrest<sup><xref ref-type="bibr" rid="bibr21-0267659112437775">21</xref></sup>. We have progressively increased warm ischemia from 15 minutes to 35-40 minutes without any drawback during the postoperative period and without modification in the need for inotropic support in the time to extubation or in the length of intensive care stay. It is noteworthy that we never experienced difficulty in maintaining cardiac arrest during warm ischemia.</p>
<p>As illustrated in this clinical case, severe thrombocytopenia in patients with cyanotic heart defects is not inevitably associated with bleeding. The best treatment is systemic oxygenation, which normalizes the platelet count within few days<sup><xref ref-type="bibr" rid="bibr23-0267659112437775">23</xref></sup>. Furthermore, warm surgery is probably associated with less severe bypass-induced coagulation alterations than is cold surgery<sup><xref ref-type="bibr" rid="bibr24-0267659112437775">24</xref></sup>.</p>
<p>However, the lowest preoperative hemoglobin level that allows safe transfusion-free surgery remains to be determined. A complicating factor is that this lowest level probably varies across clinical situations. Furthermore, the hemoglobin level is neither the best nor the only criterion to consider when determining whether a blood transfusion is needed. Venous saturation and blood lactate level are probably also relevant data which must be taken into consideration before deciding blood replacement.</p>
</sec>
<sec id="section4-0267659112437775" sec-type="conclusions">
<title>Conclusion</title>
<p>Warm surgery is likely to be less deleterious for coagulation than hypothermic perfusion and, therefore, to decrease bleeding risk. Prolonged warm ischemia proves to be safe in our experience and a study of the peak troponin level following surgery is underway in our unit. Potential drawbacks of warm surgery (that could typically be expected in cases of mechanical circuit failure) were not observed in the very substantial experience in adult warm surgery. Transfusion-free surgery is feasible in neonates and infants. However, challenges arise in determining the hemoglobin level below which blood transfusion is required.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>None.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0267659112437775">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salvin</surname><given-names>JW</given-names></name>
<name><surname>Scheurer</surname><given-names>MA</given-names></name>
<name><surname>Laussen</surname><given-names>PC</given-names></name>
<etal/>
</person-group>. <article-title>Blood transfusion after pediatric cardiac surgery is associated with prolonged hospital stay</article-title>. <source>Ann Thorac Surg</source> <year>2011</year>; <volume>91</volume>: <fpage>204</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr2-0267659112437775">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kneyber</surname><given-names>MCJ</given-names></name>
<name><surname>Hersi</surname><given-names>MI</given-names></name>
<name><surname>Twisk</surname><given-names>JWR</given-names></name>
<name><surname>Markhorst</surname><given-names>DG</given-names></name>
<name><surname>Plötz</surname><given-names>FB</given-names></name>
</person-group>. <article-title>Red blood cell transfusion in critically ill children is independently associated with increased mortality</article-title>. <source>Intensive Care Med</source> <year>2007</year>; <volume>33</volume>: <fpage>1414</fpage>–<lpage>1422</lpage>.</citation>
</ref>
<ref id="bibr3-0267659112437775">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Durandy</surname><given-names>Y</given-names></name>
</person-group>. <article-title>The impact of vacuum-assisted venous drainage and miniaturized bypass circuit on blood transfusion in pediatric cardiac surgery</article-title>. <source>ASAIO J</source>. <year>2009</year>; <volume>55</volume>: <fpage>117</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr4-0267659112437775">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Durandy</surname><given-names>Y</given-names></name>
<name><surname>Hulin</surname><given-names>S</given-names></name>
</person-group>. <article-title>Intermittent warm blood cardioplegia in the surgical treatment of congenital heart disease: clinical experience with 1400 cases</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2007</year>; <volume>133</volume>: <fpage>241</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr5-0267659112437775">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ando</surname><given-names>M</given-names></name>
<name><surname>Takahashi</surname><given-names>Y</given-names></name>
<name><surname>Suzuki</surname><given-names>N</given-names></name>
</person-group>. <article-title>Open heart surgery for small children without homologous blood transfusion by using remote pump head system</article-title>. <source>Ann Thorac Surg</source> <year>2004</year>; <volume>78</volume>: <fpage>1717</fpage>–<lpage>1722</lpage>.</citation>
</ref>
<ref id="bibr6-0267659112437775">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyaji</surname><given-names>K</given-names></name>
<name><surname>Kohira</surname><given-names>S</given-names></name>
<name><surname>Miyamoto</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Pediatric cardiac surgery without homologous blood transfusion, using a miniaturized bypass system in infants with lower body weight</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2007</year>; <volume>134</volume>: <fpage>284</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr7-0267659112437775">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hübler</surname><given-names>M</given-names></name>
<name><surname>Boettcher</surname><given-names>W</given-names></name>
<name><surname>Koster</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Transfusion-free cardiac surgery with cardiopulmonary bypass in a 2.2 kg neonate</article-title>. <source>J Card Surg</source> <year>2005</year>; <volume>20</volume>: <fpage>180</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr8-0267659112437775">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charette</surname><given-names>K</given-names></name>
<name><surname>Hirata</surname><given-names>Y</given-names></name>
<name><surname>Bograd</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>180 ml and less: cardiopulmonary bypass techniques to minimize hemodilution for neonates and small infants</article-title>. <source>Perfusion</source> <year>2007</year>; <volume>22</volume>: <fpage>327</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr9-0267659112437775">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sade</surname><given-names>RM</given-names></name>
<name><surname>Stroud</surname><given-names>MR</given-names></name>
<name><surname>Crawford</surname><given-names>FA</given-names><suffix>Jr</suffix></name>
<name><surname>Kratz</surname><given-names>JM</given-names></name>
<name><surname>Dearing</surname><given-names>JP</given-names></name>
<name><surname>Barties</surname><given-names>DM</given-names></name>
</person-group>. <article-title>A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer’s solution as priming fluid for cardiopulmonary bypass</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>1985</year>; <volume>89</volume>: <fpage>713</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr10-0267659112437775">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shander</surname><given-names>A</given-names></name>
<name><surname>Rijhwani</surname><given-names>T</given-names></name>
<name><surname>Moskowitz</surname><given-names>D</given-names></name>
<name><surname>Spence</surname><given-names>R</given-names></name>
</person-group>. <article-title>Blood and starch in cardiac surgery</article-title>. <source>Chest</source> <year>2004</year>; <volume>125</volume>: <fpage>2369</fpage>–<lpage>2370</lpage>.</citation>
</ref>
<ref id="bibr11-0267659112437775">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saunders</surname><given-names>CR</given-names></name>
<name><surname>Carliste</surname><given-names>L</given-names></name>
<name><surname>Bick</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Hydroxyethyl starch verus albumin in cardiopulmonary prime solutions</article-title>. <source>Ann Thorac Surg</source> <year>1983</year>; <volume>36</volume>: <fpage>532</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr12-0267659112437775">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanart</surname><given-names>C</given-names></name>
<name><surname>Khalife</surname><given-names>M</given-names></name>
<name><surname>De Villé</surname><given-names>A</given-names></name>
<name><surname>Otte</surname><given-names>F</given-names></name>
<name><surname>De Hert</surname><given-names>S</given-names></name>
<name><surname>Van der Linden</surname><given-names>P</given-names></name>
</person-group>. <article-title>Perioperative volume replacement in children undergoing cardiac surgery: albumin versus hydroxyethyl starch 130/0,4</article-title>. <source>Crit Care Med</source> <year>2009</year>; <volume>37</volume>: <fpage>696</fpage>–<lpage>701</lpage>.</citation>
</ref>
<ref id="bibr13-0267659112437775">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoffman</surname><given-names>TM</given-names></name>
<name><surname>Wernovsky</surname><given-names>G</given-names></name>
<name><surname>Atz</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. <article-title>Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease</article-title>. <source>Circulation</source> <year>2003</year>; <volume>107</volume>: 996–<year>1002</year></citation>
</ref>
<ref id="bibr14-0267659112437775">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kern</surname><given-names>H</given-names></name>
<name><surname>Schröder</surname><given-names>T</given-names></name>
<name><surname>Kaulfuss</surname><given-names>M</given-names></name>
<name><surname>Martin</surname><given-names>M</given-names></name>
<name><surname>Kox</surname><given-names>WJ</given-names></name>
<name><surname>Spies</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients</article-title>. <source>Crit Care Med</source> <year>2001</year>; <volume>29</volume>: <fpage>1519</fpage>–<lpage>1525</lpage>.</citation>
</ref>
<ref id="bibr15-0267659112437775">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarr</surname><given-names>TJ</given-names></name>
<name><surname>Moore</surname><given-names>NA</given-names></name>
<name><surname>Frazer</surname><given-names>RS</given-names></name>
<name><surname>Shearer</surname><given-names>ES</given-names></name>
<name><surname>Desmond</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Haemodynamic effects and comparison of enoximone, dobutamine and dopamine following mitral valve surgery</article-title>. <source>Eur J Anaesthesiol Suppl</source> <year>1993</year>; <volume>8</volume>: 15–<fpage>24</fpage></citation>
</ref>
<ref id="bibr16-0267659112437775">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barry</surname><given-names>YA</given-names></name>
<name><surname>Labow</surname><given-names>RS</given-names></name>
<name><surname>Keon</surname><given-names>WJ</given-names></name>
<name><surname>Tocchi</surname><given-names>M</given-names></name>
<name><surname>Rock</surname><given-names>G</given-names></name>
</person-group>. <article-title>Perioperative exposure to plasticizers in patients undergoing cardiopulmonary bypass</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>1989</year>; <volume>97</volume>: <fpage>900</fpage>–<lpage>905</lpage>.</citation>
</ref>
<ref id="bibr17-0267659112437775">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>Y</given-names></name>
<name><surname>Shibata</surname><given-names>T</given-names></name>
<name><surname>Sasaki</surname><given-names>Y</given-names></name>
<name><surname>Fujii</surname><given-names>H</given-names></name>
<name><surname>Bito</surname><given-names>Y</given-names></name>
<name><surname>Suchiro</surname><given-names>S</given-names></name>
</person-group>. <article-title>Di (2-ethylhexyl) phtalate exposure during cardiopulmonary bypass</article-title>. <source>Asian Cardiovasc Thorac Ann</source> <year>2008</year>; <volume>16</volume>: <fpage>4</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr18-0267659112437775">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>Y</given-names></name>
<name><surname>Shibata</surname><given-names>T</given-names></name>
<name><surname>Sasaki</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Impact of non-di- (2 ethylhexyl) phthalate cardiopulmonary bypass tubes on inflammatory cytokines and coagulation fibrinolysis systems during cardiopulmonary bypass</article-title>. <source>J Artif Organs</source> <year>2009</year>; <volume>12</volume>: <fpage>226</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr19-0267659112437775">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lichtenstein</surname><given-names>SV</given-names></name>
<name><surname>Naylor</surname><given-names>CD</given-names></name>
<name><surname>Feindel</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Intermittent warm blood cardioplegia</article-title>. <source>Circulation</source> <year>1995</year>; <volume>92</volume>: <fpage>341</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr20-0267659112437775">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casalino</surname><given-names>S</given-names></name>
<name><surname>Tesler</surname><given-names>UF</given-names></name>
<name><surname>Novelli</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>The efficacy and safety of extending the ischemic time with a modified cardioplegic technique for coronary artery surgery</article-title>. <source>J Card Surg</source> <year>2008</year>; <volume>23</volume>: <fpage>444</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr21-0267659112437775">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carrier</surname><given-names>M</given-names></name>
<name><surname>Tourigny</surname><given-names>A</given-names></name>
<name><surname>Thoribé</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Effects of cold and warm blood cardioplegia assessed by myocardial pH and release of metabolic markers</article-title>. <source>Ann Thorac Surg</source> <year>1994</year>; <volume>58</volume>: <fpage>764</fpage>–<lpage>767</lpage>.</citation>
</ref>
<ref id="bibr22-0267659112437775">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yau</surname><given-names>TM</given-names></name>
<name><surname>Ikonomidis</surname><given-names>JS</given-names></name>
<name><surname>Weissel</surname><given-names>RD</given-names></name>
<etal/>
</person-group>. <article-title>Ventricular function after normothermic versus hypothermic cardioplegia</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>1993</year>; <volume>105</volume>: <fpage>833</fpage>–<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr23-0267659112437775">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olgar</surname><given-names>S</given-names></name>
<name><surname>Ertugrul</surname><given-names>T</given-names></name>
<name><surname>Nisli</surname><given-names>K</given-names></name>
<name><surname>Devecioglu</surname><given-names>O</given-names></name>
<name><surname>Turkan</surname><given-names>E</given-names></name>
</person-group>. <article-title>Shunt operations improved thrombocytopenia in a patient with congenital cyanotic heart disease</article-title>. <source>Ann Thorac Cardiovasc Surg</source>. <year>2008</year>; <volume>14</volume>: <fpage>329</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr24-0267659112437775">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boldt</surname><given-names>J</given-names></name>
<name><surname>Knothe</surname><given-names>C</given-names></name>
<name><surname>Welters</surname><given-names>I</given-names></name>
<name><surname>Dapper</surname><given-names>FL</given-names></name>
<name><surname>Hempelmann</surname><given-names>G</given-names></name>
</person-group>. <article-title>Normothermic versus hypothermic cardiopulmonary bypass: do changes in coagulation differ?</article-title> <source>Ann Thorac Surg</source>. <year>1996</year>; <volume>62</volume>: <fpage>130</fpage>–<lpage>135</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>